World of DTC Marketing

NOVEMBER 3, 2020

An #NHLBI-funded study put a price tag on American’s bad eating habits: $50 billion a year in health care costs, attributable to cardiometabolic diseases such as heart disease, stroke and type 2 diabetes. In times of stress too many people turn to bad foods as an outlet.

Pharma Companies 190

Pharma Companies Scientist Medicine Research 190

Rethinking Clinical Trials

JANUARY 26, 2023

The primary endpoint is a composite of total events including first and recurrent MI, ischemic stroke, any arterial revascularization, and death from any cause. Participants within 10 days of index MI will either receive Evolocumab (140mg Q2W) every two weeks plus routine clinical care or standard of care.

Trials 130

Trials Clinical Trials Clinical Trials Medicine 130

World of DTC Marketing

SEPTEMBER 9, 2021

A study put a price tag on American’s bad eating habits: $50 billion a year in health care costs, attributable to cardiometabolic diseases such as heart disease, stroke, and type 2 diabetes. Then there is the cost of unhealthy Americans.

Drugs 222

Drugs Pharmacy Clinical Trials Clinical Trials 222

Rethinking Clinical Trials

FEBRUARY 20, 2024

The MINT trial investigators looked at 30-day mortality and several outcomes including MI, heart failure, stroke, bleeding, infection, and clot. Tags #pctGR, @Collaboratory1 The post Grand Rounds February 16, 2024: Clinical Implications of the MINT Trial: p=0.07 (Jeffrey Carson, MD, MACP) appeared first on Rethinking Clinical Trials.

Trials 130

Trials Clinical Trials Clinical Trials Medicine 130

Rethinking Clinical Trials

APRIL 27, 2023

The primary composite outcome was cardiovascular mortality or hospital admission with MI, stroke, or heart failure. The mean temperature for the standard group was 36.4 degrees C, and the mean temperature for cooler group was 35.8 There is a high risk of these events in the hemodialysis population with a cumulative instance at 30% at 4 years.

Trials 130

Trials Clinical Trials Clinical Trials Medicine 130

XTalks

DECEMBER 13, 2023

Current treatments for sickle cell disease include blood transfusions but patients often have episodes of intense pain and an increased risk of stroke. The FDA’s decision on the therapies came earlier than the given December 20 target decision date. Vertex-CRISPR’s Casgevy has a US list price of $2.2

Gene Therapy 98

Gene Therapy FDA Approval Gene In-Vivo 98

XTalks

AUGUST 17, 2020

To address the issues associated with these broad stroke approaches, Cue Biopharma has designed a state-of-the-art biologics protein engineering platform that leverages the natural signals that a T cell seeks as it engages in immune reactions in order to generate compounds that are highly selective for their targets. “The

Protein 98

Protein Engineer Immune Response In-Vivo 98